Double-bright (CD56bright/CD16bright) natural killer cell adoptive immunotherapy for SARS-CoV-2.

Silla, Lúcia

Silla, Lúcia.

Silla L; Hematologia e Hemoterapia, Hospital de Clínicas, Porto Alegre, Brazil.

Br J Haematol ; 190(6): e322-e323, 2020 09.

Article in English | MEDLINE | ID: covidwho-742062

Subject(s)

CD56 Antigen/analysis; COVID-19 Drug Treatment; COVID-19/therapy; Killer Cells, Natural/transplantation; SARS-CoV-2; Adaptive Immunity; COVID-19/epidemiology; COVID-19/immunology; Cell Culture Techniques/methods; Cells, Cultured/transplantation; Coculture Techniques; GPI-Linked Proteins; Humans; Immunotherapy, Adoptive/methods; Killer Cells, Natural/chemistry; Leukemia, Myeloid, Acute/immunology; Leukemia, Myeloid, Acute/therapy; Pandemics; Pulmonary Alveoli/immunology; Receptors, IgG; Virus Diseases/immunology; Virus Diseases/therapy

Keywords

NK cells; SARS-Cov-2; adoptive immunotherapy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Killer Cells, Natural / CD56 Antigen / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Type of study: Observational study Limits: Humans Language: English Journal: Br J Haematol Year: 2020 Document Type: Article Affiliation country: Bjh.17010

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google